Establishment Labs (NASDAQ:ESTA) Stock Price Down 4.6%

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares fell 4.6% on Wednesday . The stock traded as low as $40.42 and last traded at $40.82. 82,333 shares changed hands during trading, a decline of 77% from the average session volume of 354,574 shares. The stock had previously closed at $42.79.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Stephens reissued an “overweight” rating and set a $68.00 target price on shares of Establishment Labs in a research note on Wednesday, August 7th. JPMorgan Chase & Co. dropped their price objective on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Citigroup raised their target price on Establishment Labs from $41.00 to $45.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Finally, Mizuho boosted their price target on Establishment Labs from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, June 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $56.60.

Establishment Labs Trading Up 4.5 %

The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44. The business has a 50 day moving average of $43.72 and a two-hundred day moving average of $47.56. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -13.47 and a beta of 1.20.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The firm had revenue of $44.12 million during the quarter, compared to the consensus estimate of $43.10 million. Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. Establishment Labs’s revenue for the quarter was down 9.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.65) earnings per share. Equities analysts predict that Establishment Labs Holdings Inc. will post -2.2 EPS for the current year.

Insider Activity

In related news, CEO Quiros Juan Jose Chacon sold 3,866 shares of the firm’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $45.01, for a total value of $174,008.66. Following the transaction, the chief executive officer now owns 215,030 shares of the company’s stock, valued at approximately $9,678,500.30. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold 14,346 shares of company stock worth $647,806 over the last three months. 11.44% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Establishment Labs

Several large investors have recently bought and sold shares of the stock. Brown Advisory Inc. raised its holdings in shares of Establishment Labs by 63.9% in the fourth quarter. Brown Advisory Inc. now owns 2,428,792 shares of the company’s stock valued at $62,881,000 after purchasing an additional 946,612 shares during the last quarter. Capital Research Global Investors bought a new stake in Establishment Labs in the 1st quarter worth about $45,888,000. William Blair Investment Management LLC increased its stake in Establishment Labs by 14.5% in the 2nd quarter. William Blair Investment Management LLC now owns 481,572 shares of the company’s stock valued at $21,883,000 after buying an additional 60,848 shares during the last quarter. Bamco Inc. NY increased its stake in Establishment Labs by 28.4% in the 1st quarter. Bamco Inc. NY now owns 429,775 shares of the company’s stock valued at $21,876,000 after buying an additional 95,000 shares during the last quarter. Finally, Sofinnova Investments Inc. lifted its position in shares of Establishment Labs by 204.1% during the 2nd quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company’s stock worth $19,505,000 after buying an additional 288,082 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.